Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
Comprehensive Overview of SciSparc Ltd (SPRC)
SciSparc Ltd is a specialty clinical‐stage pharmaceutical company that leverages cutting‐edge cannabinoid technologies to develop innovative immunotherapy products and address central nervous system disorders. At its core, SciSparc focuses on the development of therapies derived from cannabinoid molecules, incorporating advanced biotechnology, immunotherapy, and clinical research methodologies. This dual‐focused enterprise operates across two distinct segments: one dedicated to clinical drug development and regulatory pathways, and another which drives the online sale of hemp-based consumable products.
Clinical-Stage Drug Development
The company’s primary business revolves around its clinical-stage drug development programs. SciSparc employs a portfolio based on both THC and non-psychoactive CBD compounds to create novel treatments for disorders such as Tourette Syndrome, Alzheimer’s disease with agitation, autism spectrum disorder, and status epilepticus. Utilizing a rigorous, research-driven approach, the company undertakes controlled clinical trials designed to evaluate drug efficacy, safety, and tolerability. With its IND applications and approvals for advanced clinical programs, SciSparc demonstrates its commitment to meeting stringent regulatory standards and addressing unmet medical needs in its target therapeutic areas.
Innovative Technology and Intellectual Property
SciSparc’s market positioning is strengthened by its robust portfolio of patents and proprietary technologies. The company’s innovations in cannabinoid pharmaceuticals are not only geared towards improving treatment outcomes but also distinguishing its offerings from traditional therapies. By investing in advanced research platforms, including computational drug discovery and predictive artificial intelligence models, SciSparc is able to screen and identify promising molecular candidates for further development. This technological prowess, combined with a clear focus on regulatory compliance and scientific excellence, forms the backbone of its strategic differentiation.
Online Sales and Hemp-Based Consumer Products
In addition to its core clinical operations, SciSparc diversifies its business model through a reportable segment that manages the online sale of a wide range of hemp-derived products. These products, which include hemp gummies, oil capsules, topical gels, creams for beauty and hair treatments, and other nutraceutical items, are manufactured domestically in the United States. This segment not only leverages SciSparc’s expertise in cannabinoid science but also capitalizes on the growing consumer demand for hemp-based nutritional and wellness products.
Strategic Positioning in a Competitive Landscape
SciSparc operates in a competitive and dynamic landscape where rigorous clinical research, robust intellectual property protection, and diversified revenue streams are critical. The company’s dual approach—pursuing breakthrough therapies through detailed clinical trials while also serving a broad consumer market with hemp-based products—allows it to mitigate risk and explore multiple avenues for value creation. By maintaining adherence to high standards of scientific inquiry and regulatory diligence, SciSparc reinforces its position as a trusted and innovative entity within the pharmaceutical and nutraceutical industries.
Expertise, Experience, and Trustworthiness
The expertise demonstrated by SciSparc’s team of senior executives and scientists adds a further layer of credibility to its endeavors. The company’s rigorous research protocols, combined with its strategic investments in cutting-edge technology and regulatory expertise, underscore its commitment to scientific excellence and long-term value creation. This methodical, research-intensive approach not only builds trust among stakeholders but also serves as a foundation for advancing next-generation therapies in areas that have long presented clinical challenges.
Conclusion
In summary, SciSparc Ltd exemplifies a forward-thinking pharmaceutical enterprise that effectively blends innovative drug development with consumer-oriented online sales. Its robust portfolio in cannabinoid-based immunotherapies, supported by extensive intellectual property and strategic clinical trials, positions it uniquely within a competitive market landscape. Whether addressing central nervous system disorders or fulfilling the growing consumer demand for hemp products, SciSparc’s dual business model represents a comprehensive and balanced approach to modern pharmaceutical innovation.
SciSparc (Nasdaq: SPRC) announced that AutoMax Motors, a company with which it has a pending merger agreement, received its first $13 million shipment of JAC Motors vehicles following regulatory approval for direct importation in Israel. This milestone comes after AutoMax signed distribution agreements with JAC Motors earlier in 2024. SciSparc provided financial support to AutoMax to facilitate the JAC Motors transaction. The merger agreement between SciSparc and AutoMax, signed in April 2024, would enable SciSparc's expansion into the automotive sector, subject to shareholder approval from both companies.
SciSparc (Nasdaq: SPRC) has signed an amendment to its non-binding letter of intent (LOI) to spin off its pharmaceutical portfolio through a reverse merger with Miza III Ventures Inc. (TSXV: MIZA.P). The deal values SciSparc's pharmaceutical assets at approximately US$11.6 million, while Miza's enterprise value is set at US$3.3 million.
The deadline for finalizing the definitive agreement has been extended to March 31, 2025, with transaction closing targeted for April 30, 2025. SciSparc would receive 63,300,000 Miza common shares and up to 48,000,000 contingent rights, resulting in a controlling stake of 75-84.53% in the merged entity.
The portfolio includes clinical trials for SCI-110 (Tourette syndrome and Alzheimer's) and SCI-210 (autism).
SciSparc (Nasdaq: SPRC) has received FDA approval to proceed with its Phase IIb clinical trials in the U.S. for SCI-110, a potential breakthrough treatment for Tourette Syndrome (TS) in adults. This approval comes just one month after the application submission, marking a significant milestone for the company. The trial will be conducted at three leading centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center.
The study aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients aged 18-65 years. The primary efficacy objective is to assess tic severity change using the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline. SciSparc's CEO, Oz Adler, emphasized the unmet medical need for TS management and highlighted the promising results from their Phase IIa trial, which showed an average tic reduction of 21% across the entire sample.
SciSparc (Nasdaq: SPRC) has signed a non-binding letter of intent (LOI) to sell its entire 52.73% ownership stake in MitoCareX Bio to a publicly-traded US company. The deal involves a two-phase transaction:
1. SciSparc will sell 27% of its MitoCareX shares for $700,000 in cash.
2. The remaining 73% will be exchanged for shares based on an $8 million valuation of the purchaser and a $5 million valuation of MitoCareX.
The LOI includes provisions for additional milestones that could increase the consideration from $5 million to $7 million. The MitoCareX valuation represents a 47% increase from SciSparc's initial investment. SciSparc's CEO, Oz Adler, stated that this agreement aligns with their strategy to enhance shareholder value.
SciSparc (Nasdaq: SPRC) has received FDA approval to proceed with its Phase IIb clinical trial for SCI-110, a potential Tourette Syndrome treatment. The trial will be conducted at three leading centers: Yale School of Medicine, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The study aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients aged 18-65 years.
The randomized, placebo-controlled trial will assess tic severity changes using the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline. SciSparc has already secured Institutional Review Board approvals from all three clinical sites and related federal administrations. This milestone reinforces SciSparc's ambition to become a leading provider of treatments for central nervous system disorders.
SciSparc (Nasdaq: SPRC) has submitted an Investigational New Drug application to the FDA for a phase IIb clinical trial of SCI-110, its proprietary treatment for Tourette Syndrome. The trial will be conducted at three leading centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The company has already secured necessary approvals from institutional review boards and relevant health authorities.
The trial aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients aged 18-65 years. Participants will be randomized to receive either SCI-110 or a placebo. The primary efficacy objective is to assess tic severity change using the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline. The safety objective focuses on monitoring adverse events in both treatment groups.
SciSparc (Nasdaq: SPRC) and Clearmind Medicine Inc. (Nasdaq: CMND) have announced the publication of an international patent application for a pioneering Ibogaine combination therapy. This innovative treatment aims to enhance safety and efficacy in mental health and addiction care. The patent application, filed under the Patent Cooperation Treaty, covers the combination of Ibogaine with N-Acylethanolamines.
Ibogaine, derived from the Tabernanthe iboga shrub, has shown potential in treating various substance use disorders. The collaboration between SciSparc and Clearmind focuses on developing therapies that combine psychedelic molecules with N-acylethanolamines, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind in the U.S. and other global jurisdictions.
SciSparc (Nasdaq: SPRC) has advanced an additional $1.85 million loan to AutoMax Motors , bringing the total bridge loan amount to $4.25 million. This follows a second amendment to their Bridge Loan Agreement from January 14, 2024. In exchange, AutoMax provided a first-ranking fixed charge security interest on shares of its subsidiary, AutoMax Leasing This loan fulfills the Closing Financing requirement outlined in their April 10, 2024 Merger Agreement.
Notably, AutoMax Leasing has signed a direct import agreement with JAC Motors, a major Chinese automobile manufacturer. This partnership could potentially expand AutoMax's vehicle offerings and market presence.
SciSparc (Nasdaq: SPRC) and Clearmind Medicine Inc. have announced the publication of an international patent application for an innovative MDMA-based combination treatment. This collaboration aims to enhance the safety and efficacy of mental health and addiction treatments by combining MDMA with N-Acylethanolamines, including Palmitoylethanolamide (PEA).
The partnership has already resulted in thirteen patent applications filed with the U.S. Patent and Trademark Office and other global jurisdictions. SciSparc's CEO, Oz Adler, emphasized that this approach may address FDA concerns regarding MDMA safety, potentially overcoming regulatory barriers and unlocking MDMA's full potential in clinical settings.
SciSparc (Nasdaq: SPRC) has announced a significant development in its collaboration with Clearmind Medicine Inc. Clearmind has published a patent application for innovative combinations of ketamine and N-acylethanolamines. This collaboration focuses on researching combination treatments using SciSparc's Palmitoylethanolamide (PEA) and Clearmind's psychedelic molecule, MEAI, for treating addictions, weight loss, and mental health disorders.
The partnership has already resulted in thirteen patent applications filed with the U.S. Patent and Trademark Office and other global patent offices. SciSparc's approach aims to reduce the number of doses of active ingredients while maintaining effectiveness and minimizing side effects, potentially improving treatment outcomes for various medical conditions.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
What is the primary focus of SciSparc Ltd?
How does SciSparc generate its revenue?
What types of disorders is SciSparc targeting?
How does SciSparc differentiate itself in the pharmaceutical industry?
What role do patents and proprietary technologies play at SciSparc?
How does SciSparc manage regulatory compliance?
What market segments does SciSparc serve?
How experienced is the management team at SciSparc?
